Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −0.3x | −0.4x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 3.0x | 0.6x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.1x | |
Upside (Analyst Target) | 376.2% | 133.8% | 51.1% | |
Fair Value Upside | Unlock | 22.9% | 8.9% | Unlock |